The role of Fcgamma receptors in murine autoimmune thrombocytopenia

Biburger, Markus; Aschermann, Susanne; Lux, Anja; Nimmerjahn, Falk
July 2010
Annals of Hematology;Jul2010, Vol. 89, p25
Academic Journal
journal article
Immune thrombocytopenia (ITP) can become a life-threatening condition that requires immediate medical attention. The loss in platelet numbers during ITP can be induced by a variety of triggers. Anti-platelet antibodies of several isotypes and subclasses are a major cause for ITP and are a hallmark of many complex autoimmune diseases such as systemic lupus erythematosus. Mouse models have been important to understand the effector pathways involved in antibody-mediated platelet depletion. Therapeutic interventions based on these results have been proven successful in treating human ITP, thus validating the use of these model systems. One major problem that remains to be answered is which cell populations are crucial for platelet removal. Targeting these cells directly might be a novel therapeutic strategy and will also be important to understand the underlying biological mechanisms.


Related Articles

  • Systemic lupus erythematosus and Wiskott-Aldrich syndrome in an Italian patient. Monteferrante, G.; Giani, M.; van den Heuvel, M. C. // Lupus;Mar2009, Vol. 18 Issue 3, p273 

    Systemic lupus erythematosus has not yet been associated with mutations in the Wiskott-Aldrich syndrome gene; moreover, the time courses of platelet number and size in patients with Wiskott- Aldrich syndrome are unknown. In this case, we present the time trends of platelet count and volume and...

  • Enoxaparin sodium.  // Reactions Weekly;10/7/2006, Issue 1122, p11 

    The article presents a case report of a woman who developed thrombocytopenia during anticoagulation therapy with the low molecular weight heparin and enoxaparin sodium. She had systemic lupus erythematosus and antiphospholipid antibody syndrome. After undergoing fondaparinux therapy, she had not...

  • Outcome of incomplete systemic lupus erythematosus after 10 years. Hallengren, C. St�hl; Nived, O.; Sturfelt, G. // Lupus;2004, Vol. 13 Issue 2, p85 

    The objective was to identify cases of incomplete systemic lupus erythematosus (SLE) within a defined population in southern Sweden, risk factors for development of complete SLE (=4 classification criteria) and study outcome of the patients. During prospective retrieval of SLE cases within a...

  • A case of systemic lupus erythematosus with giant hepatic cavernous hemangioma. Maeshima, E.; Minami, Y.; Sato, M.; Matsuda, K.; Uchiyama, K.; Goda, M.; Ueda, H.; Kida, Y.; Mune, M. // Lupus;2004, Vol. 13 Issue 7, p546 

    A 39-year old woman with antiphospholipid antibody positive systemic lupus erythematosus (SLE) was admitted to our department because of high fever, liver dysfunction and high level of C-reactive protein. At hospitalization, there was no anemia or jaundice. A tumor was palpable in the epigastric...

  • Agonista del receptor de trombopoyetina como tratamiento de trombocitopenia asociada a lupus eritematoso sistémico. Martínez, Maria José Moreno; Gallego, Pilar; Ramos, Manuel J. Moreno // Reumatologia Clinica;ene/feb2016, Vol. 12 Issue 1, p59 

    No abstract available.

  • Tratamiento con rituximab para la trombocitopenia secundaria a lupus eritematoso sistémico. Calderón Saldierna, Rosa Elena; Ramos Sánchez, María Azucena; Holguín, Yadhira Mejía; Aranda Baca, Laura Elena; Sauza del Pozo, María Josefina; Becerra Márquez, Ariana Maia // Reumatologia Clinica;mar/abr2010, Vol. 6 Issue 2, p82 

    Some patients with thrombocytopenia due SLE fail to respond to conventional therapies. Rituximab has been reported to be an alternative for patient treatment. Objective: To evaluate the response of thrombocytopenia due to Systemic Lupus Erythematosus to the use of Rituximab and patient relapse...

  • Management of Immune Thrombocytopenic Purpura in Adults. Stasi, Roberto; Provan, Drew // Mayo Clinic Proceedings;Apr2004, Vol. 79 Issue 4, p504 

    Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibodycoated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood...

  • Thrombotic Thrombocytopenic Purpura and Systemic Lupus Erythematosus: Distinct Entities or Overlapping Syndromes? Cheung, Winson Y. // Internet Journal of Internal Medicine;2005, Vol. 5 Issue 2, p10 

    Thrombotic thrombocytopenic purpura (TTP) and systemic lupus erythematosus (SLE) are distinct entities that share many overlapping features. The two diseases rarely coexist. To date, only twelve patients have had simultaneous presentations of TTP and SLE documented in the English literature. The...

  • Successful rituximab-CHOP treatment of systemic lupus erythematosus associated with diffuse large B-cell non-Hodgkin lymphoma. Simon, Zs.; Tarr, T.; Ress, Zs.; Gergely, L.; Kiss, E.; Illes, A. // Rheumatology International;Dec2007, Vol. 28 Issue 2, p179 

    The authors discuss the case of a 76-year-old female patient who has been suffering from subacute cutaneous lupus erythematosus since 1983. In 1999 she was diagnosed with systemic lupus erythematosus (SLE) based on her symptoms of malar rash, polyarthritis, leukopenia, autoimmune hemolytic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics